MagForce (MF6)

Business description

MagForce has a European approved nanotechnology-based therapy to treat brain cancer. Nanoparticles are injected into the tumour and activated by an external magnetic field, producing heat and thermally destroying or sensitising the tumour.

Investment summary

MagForce continues to deliver on its strategy to drive uptake of its NanoTherm nanotherapy for cancer. NanoTherm is already approved in Europe for brain cancer and a post-marketing glioblastoma (GBM) study is underway. The first commercial patients have now been treated in Germany and further revenues are targeted in 2015. Five NanoActivators are now installed in Germany. In the US, where NanoTherm therapy has been confirmed as a medical device, MagForce recently filed an IDE for NanoTherm to treat prostate cancer, which could allow a pivotal clinical trial to start in H215, if approved and assuming a small number of NanoActivators are installed this year.

Last updated on 29/06/2015

Industry outlook

MagForce’s NanoTherm therapy has been designed to directly affect tumours from within, while sparing surrounding healthy tissue. Magnetic nanoparticles are directly injected into a tumour and are then heated in the presence of an external magnetic field generated by specialist equipment (NanoActivator). This can destroy or sensitise the tumour for additional treatment.